Anakinra for resistant Kawasaki disease in an infant: case report and literature review
Exploration of Cardiology · 2025
DOI: 10.37349/ec.2025.101271 ↗Kurz gefasst
Fallbericht in der Zeitschrift Exploration of Cardiology, 2025. Verfasst von Andriana Anagnostopoulou und 4 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Resistant Kawasaki has been associated with the aggressive development of large coronary aneurysms, despite prompt treatment. In this paper, we present an infant who presented with resistant Kawasaki. Although initially he seemed to defervesce after the initial administration of intravenous immunoglobulin, he developed a new onset of fever, requiring a repeat dose of immunoglobulin. Coronary aneurysms developed rapidly, necessitating a second dose of immunoglobulins and second-line treatments such as anakinra and infliximab. High titers of COVID-19 antibodies have been a confounding factor in the management of that child, as the alternative diagnosis of multisystem inflammatory syndrome in children (MIS-C) was considered. Finally, the clinical and laboratory values were more in keeping with MIS-C.
Zitieren
APA
Anagnostopoulou, A., Andreou, N., Tsitsami, E., Tsinti, M., & Eleftherakis, N. G. (2025). Anakinra for resistant Kawasaki disease in an infant: case report and literature review. Exploration of Cardiology. https://doi.org/10.37349/ec.2025.101271
Vancouver
Anagnostopoulou A, Andreou N, Tsitsami E, Tsinti M, Eleftherakis NG. Anakinra for resistant Kawasaki disease in an infant: case report and literature review. Exploration of Cardiology. 2025. doi:10.37349/ec.2025.101271
BibTeX
@article{Anagnostopoulou2025,
author = {Anagnostopoulou, Andriana and Andreou, Nikolaos and Tsitsami, Elena and Tsinti, Maria and Eleftherakis, Nikolaos G},
title = {Anakinra for resistant Kawasaki disease in an infant: case report and literature review},
journal = {Exploration of Cardiology},
year = {2025},
doi = {10.37349/ec.2025.101271}
}
EUVIMED